CLPT Q3 FY26 earnings call: key takeaways

• EPS of -$0.24 beat the -$0.32 consensus (6:59)
• The company reported growth in revenue and progress in its drug delivery strategy. (6:59)

Results vs expectations

EPS basis: GAAP diluted EPS, SEC 10-Q

The stock moved +1.2% over the report window (S&P 500 ETF -0.4%). Earnings history

What changed since last quarter

• Raised capital via ATM facility to fund expansion and operations, ending the quarter with $46.2 million in cash. (6:59)
• Highlighted strategic focus on four pillars including drug delivery, neurosurgery navigation, laser therapy, and fluid management. (6:59)

What analysts pressed on

• Concerns about the impact of tariffs on gross margin. (21:25)
• Questions about the scalability of the Cal facility and its financial implications. (29:58)
• Uncertainty around the regulatory pathway for spine metastases treatment. (33:50)

In their words

• We have spent more than a decade building a leadership position in this market, and we are committed to maintaining and expanding that lead. (2:13)
• Our goal is to make advanced neurological therapies available to as many patients as possible... (46:30)
• You can have both speed and accuracy, particularly in bilateral procedures... (12:59)
• We believe the spinal lit market represents a substantial long-term opportunity... (14:59)